Get started
Author

Naoto Takase

Observed name: N. Takase
ORCID: 0009-0005-6484-7301
Observed ORCID: 0009-0005-6484-7301
OpenAlex ID: A5102111236
4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study
2014 · Naoto Takase, Koji Matsumoto, et al. · International Journal of Clinical Oncology · 32
Methadone for Patients with Malignant Psoas Syndrome: Case Series of Three Patients
2015 · Naoto Takase, Junichi Ikegaki, et al. · Journal of Palliative Medicine · 21
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer
2024 · Hiroaki Akamatsu, Yasuhiro Koh, et al. · Lung Cancer · 7
PDF
Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study
2024 · Akito Hata, Nobuyuki Katakami, et al. · Lung Cancer · 6
Successful surgical treatment for primary cardiac angiosarcoma: a case report
2023 · Yasuo Suehiro, Tetsuya Kajiyama, et al. · General Thoracic and Cardiovascular Surgery Cases · 6
PDF
Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer
2024 · Hidetoshi Hayashi, Makoto Nishio, et al. · Cancer Research Communications · 5
PDF
Trial Protocol of a Phase II Study of mFOLFOXIRI after Metastasectomy in Patients with Oligometastatic Colorectal Cancer (FANTASTIC Study)
2024 · Kozo Kataoka, Takeshi Yamada, et al. · Journal of the Anus Rectum and Colon · 5
PDF
Pharmacokinetics and clinical outcomes of nivolumab administered every 4 weeks in patients with advanced non-small-cell lung cancer: A four-case pilot study
2021 · Kei Irie, Akira Okada, et al. · Respiratory Investigation · 4
Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study
2016 · Naoto Takase, Yoshihiro Hattori, et al. · Respiratory Investigation · 4
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)
2025 · Masashi Ishihara, Takahisa Kawamura, et al. · Therapeutic Advances in Medical Oncology · 3
Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies
2024 · Kozo Kataoka, Takeshi Yamada, et al. · Journal of the Anus Rectum and Colon · 3
PDF
Adjuvant mFOLFOXFIRI after curative-intent resection of oligometastatic colorectal cancer: Phase II FANTASTIC trial.
2026 · Kozo Kataoka, Takeshi Yamada, et al. · Journal of Clinical Oncology · 2
PDF
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)
2023 · Nobuyuki Katakami, Takashi Nishimura, et al. · Lung Cancer · 2
A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
2019 · A. Hata, M. Satouchi, et al. · Annals of Oncology · 2
PDF
Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)
2025 · Yuji Uehara, Hiroki Izumi, et al. · Lung Cancer · 1
161TiP A phase II study of mFOLFOXIRI after metastasectomy in patients with oligometastatic colorectal cancer (FANTASTIC study)
2024 · M. Ikeda, K. Kataoka, et al. · Annals of Oncology · 1
PDF
A Resected Case of Lung Cancer with a Displaced Anomalous Bronchus of the Left Upper Lobe
2020 · Emiko Tomita, Kenjiro Fukuhara, et al. · Haigan · 1
PDF
Initial Treatment for Nasopharyngeal Carcinoma: a Single Center, Retrospective Study
2014 · Takuma Onoe, Naoto Takase, et al. · Annals of Oncology · 1
Adjuvant mFOLFOXIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial
2026 · Kozo Kataoka, Takeshi Yamada, et al. · BJS Open
Pathological Complete Response following Pembrolizumab Combined with Gemcitabine and Cisplatin Therapy for Initially Unresectable Intrahepatic Cholangiocarcinoma: A Case Report
2026 · Ikuo Nakamura, Naoto Takase, et al. · Case Reports in Oncology
Survival outcomes of first-line anti-EGFR antibody versus anti-VEGF therapy stratified by DNA methylation status in right-sided metastatic colorectal cancer: A propensity score weighting analysis.
2026 · Takeshi Suto, Kozo Kataoka, et al. · Journal of Clinical Oncology
846P Dynamics of acquired RAS, BRAF, and PIK3CA mutations in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies via longitudinal ctDNA analysis (RAS trace)
2025 · Y. Fukumoto, K. Kataoka, et al. · Annals of Oncology
823P A phase II study of mFOLFOXIRI following metastasectomy in oligometastatic colorectal cancer: (FANTASTIC)
2025 · K. Kataoka, T. Yamada, et al. · Annals of Oncology
PDF
817P Negative hyperselection by DNA methylation status for first-line anti-EGFR therapy in patients with right-sided metastatic colorectal cancer
2025 · K. Kataoka, K. Mori, et al. · Annals of Oncology
Supplementary Figure S4 from Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer
2025 · Hidetoshi Hayashi, Makoto Nishio, et al.
Works count: 63
Citation count: 106
H-index: 5
I10-index: 2
Year
Topic
Type